他莫昔芬与醋酸环丙孕酮治疗胰腺癌的前瞻性随机对照试验。
A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma.
作者信息
Keating J J, Johnson P J, Cochrane A M, Gazzard B G, Krasner N, Smith P M, Trewby P N, Wheeler P, Wilkinson S P, Williams R
机构信息
Liver Unit, King's College Hospital, Denmark Hill, London, UK.
出版信息
Br J Cancer. 1989 Nov;60(5):789-92. doi: 10.1038/bjc.1989.361.
In a prospective controlled clinical trial, 108 patients with pancreatic adenocarcinoma were randomly allocated to receive tamoxifen 20 mg b.d., cyproteron acetate 100 mg t.d.s. or no active treatment. The median survival of those receiving tamoxifen was longer than either of the other two groups (5.25 compared to 4.25 and 3 months, respectively) but this difference did not achieve statistical significance. Cox regression analysis of 12 clinical and biochemical features showed that, for the entire group of patients, survival was significantly longer in younger patients, those undergoing surgical bypass and those with better initial performance status. However, even when adjustment was made to allow for the distribution of these prognostic variables within the three groups, the difference in survival still did not achieve statistical significance. No side-effects attributable to treatment was observed.
在一项前瞻性对照临床试验中，108例胰腺腺癌患者被随机分配接受他莫昔芬每日2次、每次20毫克，醋酸环丙孕酮每日3次、每次100毫克治疗，或不接受任何积极治疗。接受他莫昔芬治疗患者的中位生存期长于其他两组（分别为5.25个月，相比之下另外两组分别为4.25个月和3个月），但这种差异未达到统计学显著性。对12项临床和生化特征进行的Cox回归分析显示，对于全体患者而言，年龄较轻、接受手术搭桥以及初始身体状况较好的患者生存期显著更长。然而，即使对这些预后变量在三组中的分布情况进行调整，生存差异仍未达到统计学显著性。未观察到任何可归因于治疗的副作用。
Zotero 插件